


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Johannsson et al
SERIAL NO: 09/050,366
FILING DATE: March 31, 1998
FOR: Use of Growth
Hormone



GROUP NO: 1654

EXAMINER: Moezie, F.

#13
1654129
RECEIVED

NOV 10 1999

TECH CENTER 1600/2900

RESPONSE

Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

This is in response to the Office Action dated October 13, 1999.


Claims 19-40 are now in the application. Applicant hereby elects the invention identified by the Examiner as Group II and drawn to a method of using GH for treating insulin resistance. Claims 19-21, 22-24 and 27-30 are directed to the elected invention. Claims 25-26 and 31-40 are drawn to non-elected inventions and may be cancelled by the Examiner upon the allowance of the claims directed to the elected invention.

In view of the above, consideration and allowance are, therefore, respectfully solicited.

In the event that the Examiner believes an interview might serve to advance the prosecution of this application in any way, the undersigned attorney is available at the telephone number noted below.

The Commissioner is hereby authorized to charge any fees or credit any overpayment associated with this communication including any extension fees to Deposit Account No. 22-0185.

Respectfully submitted,

 37134
for Burton A. Amernick, Reg. No. 24,852
Pollock, Vande Sande & Amernick
P.O. Box 19088
Washington, D.C. 20036
Telephone (202) 331-7111

Date: 11-9-99